Potent immunosuppressive activity of a phosphodiesterase‐4 inhibitor N‐acylhydrazone in models of lipopolysaccharide‐induced shock and delayed‐type hypersensitivity reaction
暂无分享,去创建一个
D. Salmon | E. Barreiro | C. Meira | E. T. Guimarães | M. Soares | D. Moreira | D. Silva | T. D. dos Santos | T. F. da Silva | Cassio S Meira | Tatiana Barbosa dos Santos
[1] S. Lata,et al. Role of IL‐1&bgr;, IL‐6 and TNF‐&agr; cytokines and TNF‐&agr; promoter variability in Plasmodium vivax infection during pregnancy in endemic population of Jharkhand, India , 2018, Molecular immunology.
[2] L. Dardenne,et al. Discovery of naphthyl‐N‐acylhydrazone p38α MAPK inhibitors with in vivo anti‐inflammatory and anti‐TNF‐α activity , 2018, Chemical biology & drug design.
[3] Hong-min Liu,et al. Discovery of tranylcypromine analogs with an acylhydrazone substituent as LSD1 inactivators: Design, synthesis and their biological evaluation. , 2017, Bioorganic & medicinal chemistry letters.
[4] Wei-Chung Cheng,et al. Corylin protects LPS-induced sepsis and attenuates LPS-induced inflammatory response , 2017, Scientific Reports.
[5] T. Vilsbøll,et al. Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes , 2017, Expert opinion on drug safety.
[6] J. Wolfender,et al. Conjugation of N-acylhydrazone and 1,2,4-oxadiazole leads to the identification of active antimalarial agents. , 2016, Bioorganic & medicinal chemistry.
[7] C. A. Fraga,et al. Discovery of Novel Orally Active Tetrahydro-Naphthyl-N-Acylhydrazones with In Vivo Anti-TNF-α Effect and Remarkable Anti-Inflammatory Properties , 2016, PloS one.
[8] D. A. Rodrigues,et al. Design, Synthesis, and Pharmacological Evaluation of Novel N-Acylhydrazone Derivatives as Potent Histone Deacetylase 6/8 Dual Inhibitors. , 2016, Journal of medicinal chemistry.
[9] A. Donato,et al. Cellular and molecular biology of aging endothelial cells. , 2015, Journal of molecular and cellular cardiology.
[10] Hikmat N. Daghestani,et al. N-(1'-naphthyl)-3,4,5-trimethoxybenzohydrazide as microtubule destabilizer: Synthesis, cytotoxicity, inhibition of cell migration and in vivo activity against acute lymphoblastic leukemia. , 2015, European journal of medicinal chemistry.
[11] Snehal S. Patel,et al. An emphasis on molecular mechanisms of anti-inflammatory effects and glucocorticoid resistance , 2015, Journal of complementary & integrative medicine.
[12] M. S. Alexandre-Moreira,et al. Novel Orally Active Analgesic and Anti-Inflammatory Cyclohexyl-N-Acylhydrazone Derivatives , 2015, Molecules.
[13] C. Fraga,et al. Antiprotozoal Activity of (E)-Cinnamic N-Acylhydrazone Derivatives , 2014, Molecules.
[14] K. Walsh,et al. The Good, the Bad, and the Ugly of interleukin‐6 signaling , 2014, The EMBO journal.
[15] L. M. Lima,et al. N-acylhydrazone derivative ameliorates monocrotaline-induced pulmonary hypertension through the modulation of adenosine AA2R activity. , 2014, International journal of cardiology.
[16] L. M. Lima,et al. Docking, Synthesis and Antiproliferative Activity of N-Acylhydrazone Derivatives Designed as Combretastatin A4 Analogues , 2014, PloS one.
[17] A. Ballester,et al. Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis , 2013, British journal of pharmacology.
[18] J. Bourguignon,et al. Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors. , 2012, Journal of medicinal chemistry.
[19] B. Narasimhan,et al. Nicotinic Acid Benzylidene/Phenyl-Ethylidene Hydrazides: Synthesis, Antimicrobial Evaluation and QSAR Studies , 2011 .
[20] Ming Yang,et al. Synthesis and Antiviral Evaluation of New N‐acylhydrazones Containing Glycine Residue , 2011, Chemical biology & drug design.
[21] M. Simon,et al. Suppression of LPS-Induced TNF-α Production in Macrophages by cAMP Is Mediated by PKA-AKAP95-p105 , 2009, Science Signaling.
[22] J. Ellena,et al. Novel 6-methanesulfonamide-3,4-methylenedioxyphenyl-N-acylhydrazones: orally effective anti-inflammatory drug candidates. , 2009, Bioorganic & medicinal chemistry.
[23] Eliezer J Barreiro,et al. Privileged structures: a useful concept for the rational design of new lead drug candidates. , 2007, Mini reviews in medicinal chemistry.
[24] D. Warhurst,et al. Modified Fixed-Ratio Isobologram Method for Studying In Vitro Interactions between Atovaquone and Proguanil or Dihydroartemisinin against Drug-Resistant Strains of Plasmodium falciparum , 2004, Antimicrobial Agents and Chemotherapy.
[25] S. Akira,et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages , 2003, Nature Immunology.
[26] M. Soares,et al. The vasoactive peptide maxadilan from sand fly saliva inhibits TNF-alpha and induces IL-6 by mouse macrophages through interaction with the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor. , 1998, Journal of immunology.
[27] M. Jordana,et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. , 1998, The Journal of clinical investigation.
[28] M. Feldmann,et al. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. , 1997, Journal of immunology.
[29] C. Dinarello,et al. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. , 1997, Chest.
[30] H. Erdjument-Bromage,et al. The Transcriptional Activity of NF-κB Is Regulated by the IκB-Associated PKAc Subunit through a Cyclic AMP–Independent Mechanism , 1997, Cell.
[31] D. Yarnall,et al. Anti‐inflammatory activity of phosphodiesterase (PDE)‐IV inhibitors in acute and chronic models of inflammation , 1995, Clinical and experimental immunology.
[32] E. F. Smith,et al. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. , 1994, International journal of immunopharmacology.
[33] S. Akira,et al. Interleukin-6 and its receptor: a paradigm for cytokines. , 1992, Science.
[34] R. Zitnik,et al. Cytokine-cytokine interactions in the context of cytokine networking. , 1992, American journal of respiratory cell and molecular biology.
[35] S. Tannenbaum,et al. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. , 1982, Analytical biochemistry.
[36] R. Titus,et al. A simple and effective method to assess murine delayed type hypersensitivity to proteins. , 1981, Journal of immunological methods.
[37] M. Rosenblatt. Anti-Infective and Anti-Inflammatory Pharmacotherapies. , 2017, Handbook of experimental pharmacology.
[38] L. Dardenne,et al. LASSBio‐1829 Hydrochloride: Development of a New Orally Active N‐Acylhydrazone IKK2 Inhibitor with Anti‐inflammatory Properties , 2016, ChemMedChem.
[39] L. Partridge,et al. Interleukin-6 signaling promotes alternative macrophage activation to limit obesity-associated insulin resistance and endotoxemia , 2016 .
[40] L. M. Lima,et al. Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates. , 2013, European journal of medicinal chemistry.
[41] M. Agarwal. The antiglucocorticoid action of mifepristone. , 1996 .
[42] V. Kuchroo,et al. Antigen Specific Suppressor Cells, Receptors, and Factors , 1989 .